Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years
- 14 May 2009
- journal article
- research article
- Published by Elsevier in Clinical Immunology
- Vol. 132 (2) , 166-173
- https://doi.org/10.1016/j.clim.2009.04.007
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 DiabetesDiabetes Care, 2008
- Growth hormone enhances thymic function in HIV-1–infected adultsJournal of Clinical Investigation, 2008
- Executive Summary: Standards of Medical Care in Diabetes—2008Diabetes Care, 2008
- Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatmentProceedings of the National Academy of Sciences, 2007
- TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ TregsJournal of Clinical Investigation, 2005
- Multiparameter evaluation of human thymic function: interpretations and caveatsClinical Immunology, 2005
- Development of population-based newborn screening for severe combined immunodeficiencyJournal of Allergy and Clinical Immunology, 2005
- Redefining the clinical remission period in children with type 1 diabetesPediatric Diabetes, 2004
- In Vitro Characterization of Five Humanized OKT3 Effector Function Variant AntibodiesCellular Immunology, 2000
- PHASE I TRIAL OF A HUMANIZED, Fc RECEPTOR NONBINDING OKT3 ANTIBODY, huOKT3??1 (Ala-Ala) IN THE TREATMENT OF ACUTE RENAL ALLOGRAFT REJECTIONTransplantation, 1999